Evoke Will Get You Going This Monday!

Evoke Pharma Inc. (EVOK) shares were down dramatically today after the FDA noted concerns about the company’s product Gimoti, which is currently awaiting FDA approval. Although the FDA’s comments are not indicative of its final conclusion, they nevertheless highlight likely areas of contention over granting approval for the drug, and as a result, investors reacted by selling the stock. The company’s shares were down nearly 60% as of the time this content was created. Here’s our recap.